Representative experience

Novartis, on its US$8.7bn acquisition of AveXis Inc., a U.S. clinical-stage gene therapy biotech company focused on developing treatments for spinal muscular atrophy.

Shire in ex-U.S. aspects of its US$2.4B oncology business sale to Servier S.A.S.

Celgene Corporation, on its US$9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.

Kite, a Gilead company, in an up to US$3bn deal to access Sangamo Therapeutics' zinc finger nuclease technology.

Celgene Corporation, on its acquisition of Impact Biomedicines, Inc. for up to US$7bn.

Chase Pharmaceuticals on its sale to Allergan for up to US$1bn.

Novartis in its US$665m acquisition of Selexys Pharmaceuticals, a developer of therapeutics to treat pain associated with certain blood and inflammatory disorders like sickle cell disease.

Allergan on its US$40.5bn generics divestiture to Teva Pharmaceuticals.

Novartis in its acquisition of Encore Vision, focused on the development of a novel treatment in presbyopia.

Alcon in the acquisition of Transcend Medical, Inc., developer of technologies for the treatment of glaucoma.

Pfizer on its immuno-oncology research collaboration and option to acquire Western Oncolytics to investigate novel oncolytic virus technology.

Nektar Therapeutics on an exclusive license agreement with Daiichi Sankyo Europe for the commercialization of ONZEALD™ within the European Economic Area, Switzerland, and Turkey.

Allergan on an exclusive license agreement with Cardiome Pharma Corp. for the commercialization of XYDALBA™ in the U.K., EU, Middle East, and Canada.

Novartis in an immune-oncology collaboration with Surface Oncology.

Sanofi in its US$2.2bn global collaboration with Regeneron Pharmaceuticals to develop novel antibody-based immuno-oncology treatments.

Novartis in the acquisition of rights from GSK to Arzerra® (ofatumumab) for auto-immune indications for more than $1bn.

Novartis in connection with its landmark portfolio transformation transactions with GSK and Eli Lilly worth more than $23bn.